"ElexoPharm is very proud to have received this prestigious transnational grant to develop medicines to treat this disease of high medical need. It is a further recognition of the excellent drug discovery capabilities of our growing company", states Axel Koch, Managing Director of ElexoPharm.
About Elexopharm
ElexoPharm GmbH is a German biotech company located in Saarbrücken, founded as a spin-off of the Department of Pharmaceutical and Medicinal Chemistry of Saarland University headed by Professor Rolf Hartmann. ElexoPharm is focused on the preclinical discovery and optimization of novel innovative drugs for human diseases, which are currently not or insufficiently treatable with existing drugs. One of the largest success of ElexoPharm was the execution of an exclusive license and collaboration agreement with Merck & Co. Inc. for one of its own research projects (development of aldosterone synthase inhibitors for the treatment of cardiovascular diseases) in 2010.
Contact
Axel Koch, MBA
Managing Director
ElexoPharm GmbH
Im Stadtwald, A1.1
66123 Saarbrücken
Germany
Phone: +49 (0) 681 - 302 68320
Fax: +49 (0) 681 - 910 2894
Email: info@elexopharm.de
www.elexopharm.de
